



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

**Oversight Committee Meeting Minutes
February 19, 2020**

NOTE: Unless the information is confidential, the reports, presentations, and grant award information referenced in the minutes are available at <http://ocmeetings.cprit.texas.gov> in the "Oversight Committee Board Packet" section for the corresponding meeting date.

Call to Order – Agenda Item 1

A quorum being present, Presiding Officer Dee Margo called the Oversight Committee to order at 9:06 a.m.

Roll Call/Excused Absences – Agenda Item 2

Committee Members Present

Angelos Angelou
David Cummings, M.D.
Ambrosio Hernandez, M.D.
Donald (Dee) Margo
Will Montgomery
Mahendra Patel, M.D.
Bill Rice, M.D.
Craig Rosenfeld, M.D.

Oath of Office for newly appointed Oversight Committee member - Agenda Item 3

Presiding Officer Dee Margo administered the oath of office for Dr. Ambrosio Hernandez.

Adoption of Minutes from the November 20, 2019 Meeting – Agenda Item 4 – Tab 1

MOTION:

On a motion by Will Montgomery and seconded by Dr. Bill Rice, the Oversight Committee unanimously voted to approve the minutes of the Oversight Committee meeting of November 20, 2019, as presented.

Chief Executive Officer Report – Agenda Item 6, Tab 2

Presiding Officer Margo recognized Chief Executive Officer Wayne Roberts to present the CEO's report. Mr. Roberts reviewed the amount of agency funds available for the proposed grant awards. He noted that CPRIT distributed the statutorily required FY 2019 annual report to state leadership as well as posted it on the CPRIT website. He acknowledged Deputy Executive Officer and General Counsel Kristen Doyle, Programmer Christopher Bair, and Executive Assistant Melanie

Cleveland for their work finalizing the annual report. Mr. Roberts also presented the Health & Safety Code Section 102.260(c) report.

Chief Compliance Officer Report and Compliance Certification For the Proposed Grant Awards – Agenda Item 7, Tab 3

Presiding Officer Margo recognized Chief Compliance Officer Vince Burgess to present the Compliance Report and Compliance Certification of Grant Award Process. Mr. Burgess presented the Compliance Report for the past quarter’s activities. He highlighted two areas: Training and Support and Delinquent Reporting. He discussed the chart on page 3-3, *Grant Recipient Report Monitoring FY20- 9-19 thru 1-20 Delinquent/Missing Reports*.

Mr. Burgess also presented the Compliance Certification for the proposed academic research, prevention and product development grant awards, confirming that the proposed awards and review process complied with all applicable state and agency requirements.

Chief Scientific Officer Report and Award Recommendations – Agenda Item 8, Tab 4

Presiding Officer Margo recognized Chief Scientific Officer Dr. James Willson to present the academic research award recommendations and program update.

Dr. Willson referred members to Tab 4 page 4-1 of the meeting packet and provided an update for the Academic Research Program. He reviewed FY20.2 application submissions by mechanism and funding requested and provided an overview of FY21.1 RFAs.

Dr. Willson referred members to the “Proposed Grant Award” packet and presented the academic research award slates recommended by the Scientific Review Council (SRC). He directed members to the first column of Table 1 on page 8, which displayed the SRC’s 54 award recommendations for FY20.1 and recruitment cycles 20.4, 20.5 and 20.6, representing seven grant mechanisms totaling \$65,554,090.

Dr. Willson noted that because the SRC recommendations exceeded the funds budgeted for Academic Research Program awards for the second quarter of 2020, the Program Integration Committee (PIC) voted to defer action on 13 applications recommended by the SRC totaling \$12,835,005 that had overall scores of 2.8 and higher. As a result of the PIC’s deferment, Dr. Willson presented 41 awards totaling \$52,719,085.

Cycle FY20.1 Recommended Academic Research Awards

Application ID	Award Mechanism	Score	Application Title	PI	PI Organization	Recommended Budget
RP200423	IIRA	1.2	Adipocyte-Producing Noncoding RNA Promotes Liver Cancer Immunoresistance	Liuqing Yang	The University of Texas M. D. Anderson Cancer Center	\$900,000
RP200093	IIRA	1.6	Targeting Multiple Myeloma Stem Cell Niche	Nami McCarty	The University of Texas Health Science Center at Houston	\$900,000

RP200081	IIRA	1.7	Nucleostemin: A New Tumor Addictive Mechanism, Outcome Predictor, and Therapeutic Target for Hepatocellular Carcinoma	Robert Tsai	Texas A&M University System Health Science Center	\$900,000
RP200395	IIRA	1.7	Artificial Intelligence for the Peer Review of Radiation Therapy Treatments	Laurence Court	The University of Texas M. D. Anderson Cancer Center	\$900,000
RP200233	IIRA	1.8	Advance CT and Fluorescence Imaging of Kidney Cancers With Glutathione-Mediated Contrast Enhancements	Jie Zheng	The University of Texas at Dallas	\$900,000
RP200120	IIRA	1.9	Single-Cell Evaluation to Identify Tumor-Stroma Niches Driving the Transition From In Situ to Invasive Breast Cancer	Helen Piwnicka-Worms	The University of Texas M. D. Anderson Cancer Center	\$900,000
RP200023	IIRA	1.9	Off-the-Shelf, Cord-Derived iNK T Cells Engineered to Prevent GVHD and Relapse After Hematopoietic Stem Cell Transplantation	Jin Seon Im	The University of Texas M. D. Anderson Cancer Center	\$900,000
RP200271	IIRA	1.9	Development of a Novel Strategy for Tumor Delivery of MHC-I–Compatible Peptides for Cancer Immunotherapy	Zhen Fan	The University of Texas M. D. Anderson Cancer Center	\$900,000
RP200103	IIRACCA	2.0	Targeting Twist2 Pathway as a Potential Therapy of Rhabdomyosarcoma	Eric Olson	The University of Texas Southwestern Medical Center	\$1,137,104
RP200401	IIRA	2.0	Targeting MEK in EGFR-Amplified Glioblastoma	John de Groot	The University of Texas M. D. Anderson Cancer Center	\$900,000
RP200170	IIRA	2.0	Tumor-Secreted LIF Activates a Cytokine-Adipose-Hypothalamic Axis to Induce Cancer Cachexia	Rodney Infante	The University of Texas Southwestern Medical Center	\$900,000
RP200467	IIRA	2.0	SREBP-2–Dependent Oncometabolites and Intestinal Tumorigenesis	Luke Engelking	The University of Texas Southwestern Medical Center	\$900,000
RP200197	IIRA	2.0	Role of CMPK2 in Liver Inflammation and Hepatocellular Carcinoma	Shuang Liang	The University of Texas Southwestern Medical Center	\$900,000
RP200173	IIRACT	2.0	Modulating the Gut-Tumor Microbial Axis to Reverse Pancreatic Cancer Immunosuppression	Florencia McAllister	The University of Texas M. D. Anderson Cancer Center	\$2,067,105

RP200369	IIRACT	2.0	Targeting Alterations of the NOTCH1 Pathway in Head and Neck Squamous Cell Carcinoma (HNSCC)	Faye Johnson	The University of Texas M. D. Anderson Cancer Center	\$1,200,000
RP200223	IIRA	2.0	High-Sensitivity 19F MRI for Clinically Translatable Imaging of Adoptive NK Cell Brain Tumor Therapy	Konstantin Sokolov	The University of Texas M. D. Anderson Cancer Center	\$887,713
RP200021	IIRA	2.0	Optimizing Therapeutic Strategies Against Lung Cancer Using Multimodality Imaging	Li Zhang	The University of Texas at Dallas	\$900,000
RP200402	IIRA	2.1	Targeting Endothelial Transcriptional Networks in GBM	Joshua Wythe	Baylor College of Medicine	\$899,847
RP200390	IIRA	2.1	Heterogeneity of Enhancer Patterns in Colorectal Cancers—Mechanisms and Therapy	Kunal Rai	The University of Texas M. D. Anderson Cancer Center	\$898,872
RP200284	IIRA	2.1	Molecular Mechanism of NLRP12-Mediated Regulation of Colorectal Cancer	Hasan Zaki	The University of Texas Southwestern Medical Center	\$899,959
RP200110	IIRACCA	2.2	ALKBH5 as a Novel Promoter of Osteosarcoma Growth and Metastasis	Manjeet Rao	The University of Texas Health Science Center at San Antonio	\$1,200,000
RP200235	IIRA	2.2	Investigating the Role of CD38 as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer	Don Gibbons	The University of Texas M. D. Anderson Cancer Center	\$900,000
RP200150	IIRA	2.2	Molecular Features Impacting Drug Resistance in Atypical EGFR Exon 18 and Exon 20 Mutant NSCLC and the Development of Novel Mutant-Selective Inhibitors	John Heymach	The University of Texas M. D. Anderson Cancer Center	\$900,000
RP200452	IIRA	2.2	Noninvasive Imaging and Quantification of the Cancer Mechanical Microenvironment to Monitor Cancer Progression and Predict Cancer Treatments	Raffaella Righetti	Texas A&M Engineering Experiment Station	\$900,000
RP200315	IIRA	2.3	CRAD Tumor Suppressor and Mucinous Adenocarcinoma	Jae-II Park	The University of Texas M. D. Anderson Cancer Center	\$900,000
RP200409	IIRAP	2.4	Transdiagnostic Cognitive Behavioral Therapy for Smokers With Anxiety and Depression	Matthew Gallagher	University of Houston	\$890,502

RP200381	IIRACCA	2.4	Doxorubicin-Induced Cardiotoxicity: Defining Blood and Echocardiogram Biomarkers in a Mouse Model and AYA Sarcoma Patients for Evaluating Exercise Interventions	Eugenie Kleinerman	The University of Texas M. D. Anderson Cancer Center	\$1,444,593
RP200443	IIRA	2.4	Spatial Profiling of Tumor-Immune Microenvironment by Multiplexed Single-Cell Imaging Mass Cytometry	Hyun-Sung Lee	Baylor College of Medicine	\$897,527
RP200456	IIRA	2.4	Clinical MR Spectroscopy Development of Malignancy Biomarkers in Gliomas	Changho Choi	The University of Texas Southwestern Medical Center	\$899,651
RP200287	IIRA	2.5	Elucidating Aberrant Splicing-Induced Immune Pathway Activation in RBM10-Deficient KRAS-Mutant NSCLC and Harnessing Its Potential for Precision Immunotherapy	Ferdinandos Skoulidis	The University of Texas M. D. Anderson Cancer Center	\$900,000
RP200181	IIRA	2.5	Can Microsurgeries Cure Lymphedema? An Objective Assessment	Melissa Aldrich	The University of Texas Health Science Center at Houston	\$900,000
RP200047	IIRA	2.6	KRAS Spatiotemporal Dynamics: Novel Therapeutic Targets	John Hancock	The University of Texas Health Science Center at Houston	\$900,000
RP200118	IIRA	2.6	PPAR-Alpha Modulation of DNA Sensing and Interferon Induction	Tiffany Reese	The University of Texas Southwestern Medical Center	\$900,000
RP200356	IIRACT	2.6	Circulating Tumor DNA–Defined Minimal Residual Disease in Colorectal Cancer	Arvind Dasari	The University of Texas M. D. Anderson Cancer Center	\$2,399,998
RP200439	IIRA	2.7	Targeting AKT Signaling in MAPK4-High Triple-Negative Breast Cancer	Feng Yang	Baylor College of Medicine	\$900,000
RP200432	IIRACCA	2.7	GD2 Expression and Response to Chemoimmunotherapy in Neuroblastoma	Charles Reynolds	Texas Tech University Health Sciences Center	\$1,196,214

IIRA: Individual Investigator Research Awards, IIRACCA: Individual Investigator Research Awards for Childhood and Adolescent Cancers, IIRACT: Individual Investigator Research Awards for Clinical Translation, IIRAP: Individual Investigator Awards for Prevention and Early Detection.

Cycle FY 20.4, 20.5 and 20.6 Recommended Recruitment Awards

App ID	Candidate	Mechanism	Organization	Budget	Overall Score
RR200029	Eric Smith, M.D., Ph.D.	RFTFM	The University of Texas M.D. Anderson Cancer Center	\$2,000,000	1.5
RR200025	Anna-Karin Gustavsson, Ph.D.	RFTFM	Rice University	\$2,000,000	1.5
RR200030	Shaun Olsen, Ph.D.	RRS	The University of Texas Health Science Center at San Antonio	\$4,000,000	2.0
RR200032	Karl Scheid, Ph.D.	REI	The University of Texas at San Antonio	\$6,000,000	2.0
RR200035	Adam Durbin, M.D., Ph.D.	RFTFM	The University of Texas Southwestern Medical Center	\$2,000,000	2.0

REI- Recruitment of Established Investigators, RRS- Recruitment of Rising Stars, RFTFM- Recruitment of First-Time Tenure Track Faculty Members

Dr. Willson responded to an Oversight Committee member’s question about the meaning of “high impact” in terms of the High-Impact, High-Risk research award, noting that while it could be interpreted in different ways, he viewed it as having the potential to benefit a large number of patients.

Conflict of Interest Notification

Presiding Officer Margo noted for the record that no Oversight Committee members reported conflicts of interest with any proposed academic research awards.

Approval Process – Academic Research Awards

Presiding Officer Margo called for a vote on the award recommendations.

MOTION:

On a motion made by Dr. Rice and seconded by Mr. Angelou, all Oversight Committee members present and able to vote unanimously approved the PIC’s recommendations for the seven academic research award slates.

Presiding Officer Margo noted for the record that Dr. Hernandez was unable to review the academic research award recommendations before the meeting and did not vote on the recommendations.

MOTION:

On a motion made by Dr. Rice and seconded by Mr. Angelou, all Oversight Committee members voted to approve the delegation of contract negotiation authority to CPRIT’s CEO and staff and authorized the CEO to sign the contracts on behalf of CPRIT.

Chief Prevention Officer Report and Award Recommendations – Agenda Item 9, Tab 5

Presiding Officer Margo recognized Chief Prevention Officer Ramona Magid to present the Prevention Program award recommendations and provide an update on the program.

Ms. Magid updated members on the Prevention Program activities, including the formation of the Prevention Advisory Committee. She also presented the ten prevention program projects, representing four grant mechanisms, that the Prevention Review Council and PIC recommended for award funding totaling \$13,507,769. Ms. Magid reported that all the recommended applications address one or more of the Prevention Program priorities.

Cycle 20.1 Recommended Prevention Program Awards

App. ID	Mech	Application Title	PD	Organization	Score	Rank Order	Budget
PP200006	EPS	De Casa en Casa 3: Cervical Cancer Screening in Underserved Rural and Border Communities in West and South Texas	Shokar, Navkiran	Texas Tech University Health Sciences Center at El Paso	1.9	1	\$1,985,089
PP200055	DI	Advancing the Access to Cancer Training, Information, Outreach, and Navigation (ACTION) Project for CHW Dissemination of Resources to At-Risk Texas Regions	Bolin, Jane	Texas A&M University System Health Science Center	2.0	2	\$300,000
PP200028	EPS	Active Living After Cancer: Combining a Physical Activity Program with Survivor Navigation	Basen-Engquist, Karen	The University of Texas M. D. Anderson Cancer Center	2.3	3	\$1,999,200
PP200005	EPS	Maximizing opportunities for HPV vaccination in medically underserved counties of Southeast Texas	Berenson, Abbey	The University of Texas Medical Branch at Galveston	2.7	4	\$1,993,096
PP200017	EPS	Expanding "All for Them": A comprehensive school-based approach to increase HPV vaccination through public schools	Cuccaro, Paula	The University of Texas Health Science Center at Houston	2.8	5	\$1,960,631
PP200051	DI	Taking Texas Tobacco Free Through a Sustainable Education/Training Program Designed for Personnel Addressing Tobacco Control in Behavioral Health Settings	Reitzel, Lorraine	University of Houston	3.0	6	\$299,953
PP200034	EBP	Advancing Breast Health among Uninsured Women	Jacobs, Elizabeth	The University of Texas at Austin	3.1	7	\$995,999
PP200040	TCL	BEXAR COUNTY'S NAVIGATION TO CESSATION (N2C)	Scott, Anthony	University Health System	3.2	8	\$973,809
PP200009	EPS	The Expanded C-SPAN Coalition: Colorectal Screening and Patient Navigation	Argenbright, Keith	The University of Texas Southwestern Medical Center	3.2	9	\$2,000,000

App. ID	Mech	Application Title	PD	Organization	Score	Rank Order	Budget
PP200036	EBP	Screening and Treatment for Unhealthy Alcohol Use as a Means of Cancer Prevention	Pignone, Michael	The University of Texas at Austin	3.4	10	\$999,992

EBP: Evidence-Based Cancer Prevention Services

EPS: Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations

TCL: Tobacco Control and Lung Cancer Screening

DI: Dissemination of CPRIT-Funded Cancer Control Interventions

Compliance Certification

Presiding Officer Margo reminded members that Mr. Burgess previously certified compliance of the prevention awards process.

Conflict of Interest Notification

Presiding Officer Margo noted for the record that no Oversight Committee members reported conflicts of interest with any proposed prevention awards.

Approval Process – Prevention Grant Awards

After the Oversight Committee agreed to consider the four slates together, Presiding Officer Margo called for a vote on the proposed award recommendations.

MOTION:

On a motion made by Dr. Rice and seconded by Mr. Angelou, the Oversight Committee unanimously voted to approve the PIC’s recommendation for the ten prevention awards.

Presiding Officer Margo noted for the record that Dr. Hernandez was unable to review the prevention award recommendations before the meeting and did not vote on the recommendations.

MOTION:

On a motion made by Dr. Rice and seconded by Mr. Angelou, the Oversight Committee unanimously voted to approve the delegation of contract negotiation authority to CPRIT’s CEO and authorized the CEO to sign the contracts on behalf of CPRIT.

Chief Product Development Officer Report and Award Recommendations – Agenda Item 10, Tab 6

Presiding Officer Margo recognized Chief Product Development Officer Dr. Cindy WalkerPeach to present the proposed Product Development Research Program award recommendations and to provide an update on the program.

Dr. WalkerPeach presented the PIC’s four product development award recommendations, including award contingencies, totaling \$11,996,760 for review cycle 20.1: Asyilia Therapeutics, Inc., Dialectic Therapeutics, Inc., Texas Magnetic Imaging Technology, Inc., and Barricade Therapeutics, Corp.

In addition, Dr. WalkerPeach noted that the PDRC declined to act on one application, DP200034, pending review of additional information requested from the applicant. She indicated that once the applicant provides the requested information, the PDRC will reconvene, evaluate the data, and make a recommendation. Dr. WalkerPeach anticipates that the PDRC will provide their award recommendation regarding the pending application for consideration at either the upcoming May or August meetings.

Cycle FY20.1 Recommended Product Development Research Awards

Rank	Application ID	Mechanism (Cycle)	Company Name	Project	Maximum Recommended Budget	Overall Score*
1	DP200033	SEED (20.1)	Asyilia Therapeutics, Inc.	Development of a Novel Approach to Cancer Immunotherapy by Targeting Extracellular Tumor-derived HSP70 to Dendritic Cells	\$3,000,000	2.9
2	DP200046	SEED (20.1)	Texas Magnetic Imaging Technology, Inc.	Integrated interior magnetic resonance imaging and medical linear accelerator system for radiation therapy	\$2,997,384	3.0
3	DP200018	SEED (20.1)	Dialectic Therapeutics, Inc.	Developing a First-in-Class BCL-XL Proteolysis Targeting Chimera (BCL-PROTAC) for Cancer Therapy	\$3,000,000	2.3
4	DP200056	SEED (20.1)	Barricade Therapeutics, Corp.	Development of a First-in-Class Small Molecule, TASIN, for Targeting Truncated APC Mutations for the Treatment of Colorectal Cancer (CRC)	\$2,999,376	2.0
Total					\$11,996,760	

Dr. WalkerPeach responded to an Oversight Committee member’s question that a previous CPRIT award did not give an applicant any advantage during the review of for a second award.

An Oversight Committee member inquired about the matching funds associated with product development awards and any revenue sharing requirement. Dr. WalkerPeach confirmed that CPRIT requires award recipients must raise a portion of the total budget from external sources. For a company receiving an initial CPRIT award, the company must contribute \$1.00 in matching funds for every \$2.00 received from CPRIT. She also verified that all award contracts include a revenue-sharing agreement.

Compliance Certification

Presiding Officer Margo reminded members that Mr. Burgess previously certified compliance of the product development awards process.

Conflict of Interest Notification

Presiding Officer Margo noted for the record that no Oversight Committee members reported conflicts of interest with any proposed product development research awards.

Approval Process –Product Development Research Awards

Presiding Officer Margo called for a vote on the proposed award recommendations.

MOTION:

On a motion made by Mr. Montgomery and seconded by Dr. Rice the Oversight Committee unanimously voted to approve the PIC's recommendations for the four applications presented, totaling \$11,996,760 in award funding.

Presiding Officer Margo noted for the record that Dr. Hernandez was unable to review the product development research award recommendations before the meeting and did not vote on the recommendations.

MOTION:

On a motion made by Dr. Rice and seconded by Mr. Montgomery the Oversight Committee unanimously voted to approve the delegation of contract negotiation authority to CPRIT's CEO and staff and authorized the CEO to sign the contracts on behalf of CPRIT.

MOTION:

On a motion made by Dr. Rice and seconded by Mr. Montgomery the Oversight Committee unanimously voted to approve the disbursement of grant funds via advance payments to the four companies approved for awards upon execution of the award contracts and the successful completion of tranches.

Following the awards, Dr. WalkerPeach updated the Oversight Committee on the status of applications under review in the 20.2 cycle. In addition, Dr. WalkerPeach notified members of the nomination of seven new members of the Product Development Advisory Committee as well as expansion of the Product Development Review Council by two members. Dr. WalkerPeach finished her report with the presentation of the proposed review timeline and three product development RFAs for the first and second cycles of FY 2021.

MOTION:

On a motion made by Dr. Rice and seconded by Mr. Angelou the Oversight Committee unanimously voted to approve the proposed timeline and Product Development Research Program RFAs for the first and second cycles of FY 2021.

Scientific Research and Prevention Program Committee Appointments – Agenda Item 11

This is a standing item that has no information for this meeting.

Advisory Committees Appointments – Item 12, Tab 7

Presiding Officer Margo recognized Mr. Roberts to present the Presiding Officer's appointments to the Prevention Advisory Committee and the Product Development Advisory Committee. He also provided notice of the three new appointments to the University Advisory Committee.

MOTION:

On a motion made by Dr. Rice and seconded by Dr. Hernandez the Oversight Committee unanimously voted to approve the appointments to the Prevention and Product Development advisory committees.

Amendments to 25 T.A.C. Chapter 703 – Item 15, Tab 10

Presiding Officer Margo recognized CPRIT assistant general counsel Cameron Eckel to discuss the proposed rule amendments. Ms. Eckel reviewed the proposed rule amendments to Texas Administrative Code Chapter 703.11 and 703.23.

An Oversight Committee member asked about matching funds verification forms. Ms. Eckel explained that grantees must submit a matching certification form at the beginning of the project year certifying they have the matching funds and then a matching verification form at the end of the project year documenting expenditures of their own matching funds.

MOTION:

On a motion by Dr. Rice and seconded by Dr. Patel, the Oversight Committee unanimously voted to approve the publication of the proposed changes to the Texas Administrative Code Chapter 703 in the Texas Register.

Internal Auditor Report – Agenda Item 13, Tab 8 (taken out of order)

Presiding Officer Margo recognized CPRIT internal auditor Dan Graves with Weaver and Tidwell. Mr. Graves provided a timeline for audits and follow-up procedures to be performed under the 2020 Internal Audit Plan. He noted that the governance audit begins March 2, with the communication and state reporting follow-up audits starting March 16, and both the disaster recovery and business continuity planning and information security follow-up audits will begin on May 4. Mr. Graves concluded his report, stating that there have been no other changes since his last report to the Oversight Committee members in November.

CPRIT 2.0 Planning – Item 14, Tab 9 (taken out of order)

Presiding Officer Margo recognized Mr. Roberts to present the CPRIT 2.0 Planning Project Overview. Mr. Roberts discussed CPRIT’s plan for creating the framework for the next 10 years of CPRIT’s mission. He encouraged participation from the Oversight Committee members and predicted an initial draft document would be presented to members at the May Oversight Committee meeting to give them an idea of initial thoughts on CPRIT’s next phase. Mr. Roberts explained the vision to have forums and receive input from many various sources, including, but not limited to, the public and advocates.

Public Comment – Agenda Item 5 (taken out of order)

Presiding Officer Dee Margo recognized Ms. Susan Dawson for public comment. She provided suggestions for CPRIT when planning the next 10 years, encouraging the agency to be bold, focus on prevention, engage community providers, have more intense collaboration and data sharing, and fund health delivery system research.

An Oversight Committee member asked Ms. Dawson what she meant by “efficient delivery.” She responded that it is related to patient outcomes and dollars and referenced the book, *Priced Out*, for more information.

Amendments to Oversight Committee Bylaws – Agenda Item 16, Tab 11

Presiding Officer Dee Margo recognized Ms. Doyle, to present the amendments to the Oversight Committee Bylaws. Ms. Doyle reviewed the proposed changes to the Oversight Committee bylaws to allow the option for holding open meetings by videoconference call as allowed by the Texas Open Meetings Act.

Ms. Doyle responded to an Oversight Committee member’s question, explaining that if the Presiding Officer and Vice Presiding Officer are not present, then the Chair of the Academic Research subcommittee would preside over the open meeting. If the Academic Research Subcommittee Chair was not present, then the Product Development Research Subcommittee Chair would preside.

Another Oversight Committee member observed how valuable it is to meet in person but acknowledged that having a videoconference option is helpful.

In response to an Oversight Committee member’s question about state law governing open meetings, Ms. Doyle referred members to the Texas Open Meeting Act.

MOTION:

On a motion by Mr. Montgomery and seconded by Dr. Rice, the Oversight Committee unanimously voted to approve the changes to the Oversight Committee bylaws.

Communications Report – Agenda Item 17, Tab 12

Presiding Officer Margo recognized Senior Communications Specialist Chris Cutrone to present the communications report. Mr. Cutrone discussed the steady increase in content generation and more active engagement with CPRIT followers. He highlighted the relaunch of the agency LinkedIn page in June of 2019 which has more than doubled in followers.

Mr. Cutrone responded to an Oversight Committee member’s question, noting that Hahn Public Communications assists CPRIT with communication activities pursuant to a contract.

Another member asked about which social platform provides the most engagement opportunities for the agency. Mr. Cutrone responded that CPRIT’s Twitter account has the most hits.

Chief Operating Officer Report – Agenda Item 18, Tab 13

Presiding Officer Margo recognized Chief Operating Officer Heidi McConnell to present her report. Ms. McConnell stated that CPRIT was on track with its budget. The Legislative Budget Board approved the \$2.4 million transfer from the award cancer research grants budget line item to the grant review and award operations budget line item. She reminded members that the CPRIT budget includes an annual transfer of \$3.1 million to the Department of State Health Services, which was increased by the legislature. CPRIT received approximately \$30,000 in revenue sharing during the first quarter of FY2020 for a total of \$3.7 million received to date. She also reviewed the debt issuance history. Ms. McConnell went on to explain that the state budget cycle has started, and the

agency received instructions for the strategic plan, which is due June 1. The agency is waiting to receive instructions for the Legislative Appropriations Request. Finally, Ms. McConnell provided an update on the 2020 CPRIT conference.

Subcommittee Business – Agenda Item 19, Tab 14

Presiding Chair Margo proposed Dr. Ambrosio Hernandez join the Academic Research and Prevention subcommittees.

MOTION:

On a motion by Dr. Rice and seconded by Mr. Montgomery, the Oversight Committee unanimously voted to approve Dr. Hernandez’s subcommittee appointments.

Compliance Investigation Pursuant to Health & Safety Code 102.2631 – Agenda Item 20 and Consultation with General Counsel – Agenda Item 21

Presiding Officer Margo announced that the Oversight Committee will take up Agenda Items 20 and 21 in closed session. Presiding Officer Margo moved into closed session pursuant to Texas Open Meetings Act Section 551.071 to consult with general counsel and Texas Health and Safety Code Section 102.2631 to discuss an ongoing compliance investigation. He asked that Mr. Roberts, Ms. Doyle, Mr. Burgess and Ms. McConnell join the closed session, which he convened at 10:39 a.m. The Oversight Committee reconvened the open meeting at 11:25 a.m.

Future Meeting Dates and Agenda Items – Agenda Item 22

The next regular Oversight Committee meeting is Wednesday, May 20.

Adjournment – Agenda Item 23


MOTION:

There being no further business, the Oversight Committee unanimously voted to approve a motion to adjourn made by Presiding Officer Margo and seconded by Dr. Rice.

Meeting adjourned at 11:26 a.m.



Signature



Date